Axinn Successfully Obtains Dismissal of Certain Patent Claims asserted against Zydus Pharmaceuticals in Boehringer Ingelheim Pharmaceuticals, Inc. v. HEC Pharma Co., Ltd.
December 19, 2016
A team of Axinn attorneys successfully obtained a dismissal of certain patent claims brought by Boehringer Ingelheim Pharmaceuticals against several defendants, including Axinn client Zydus Pharmaceuticals. On December 7, the United States District Court for the District of New Jersey granted the Defendants’ joint motion to dismiss the claims of patent infringement relating to U.S. Patent No. 8,853,156, which is alleged by Boehringer to cover its antidiabetic drug Tradjenta (linagliptin).
At issue in the matter was whether claims that recite a method of treating metabolic diseases by administering DPP-IV inhibitors to certain patients are patent eligible under 35 U.S.C. § 101. The Defendants challenged the asserted certain of the ‘156 patent on grounds that they recite a natural law and are therefore patent ineligible. The plaintiffs argued that the claims were patent eligible because they recite treating specific populations using non-natural compounds and alter the state of the body in a new and useful way.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Hartford HealthCare Black and Red Gala 2025
Sponsorship
Antitrust
Informa CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
IAM Live: Auto IP USA 2025
Speaking Engagement
Intellectual Property
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property